| Budget Amount *help |
¥72,100,000 (Direct Cost: ¥72,100,000)
Fiscal Year 2009: ¥14,400,000 (Direct Cost: ¥14,400,000)
Fiscal Year 2008: ¥14,400,000 (Direct Cost: ¥14,400,000)
Fiscal Year 2007: ¥14,500,000 (Direct Cost: ¥14,500,000)
Fiscal Year 2006: ¥14,500,000 (Direct Cost: ¥14,500,000)
Fiscal Year 2005: ¥14,300,000 (Direct Cost: ¥14,300,000)
|
|---|
| Research Abstract |
We found that phospholipase C・, an effector of the ras oncogene product (Ras), plays a crucial and universal role in tumor promotion through triggering inflammatory reactions, and analyzed the underlying action mechanisms. Furthermore, we elucidated the molecular mechanism for the conformational dynamics of the GTP-bound Ras. By using a new strategy based on this mechanism, we developed small molecule Ras inhibitors, which exhibit equivalent or even higher anti-tumor activities in animal models compared to the existing anti-cancer drugs, through an in silico approach.
|
